INGELHEIM, Germany--(BUSINESS WIRE)--For media excluding US/Canada and UK Boehringer Ingelheim announced data which add to the growing body of evidence that show ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352 ...

Boehringer Ingelheim's COPD treatment, Spiolto Respimat, is up against a raft of competitors--especially in the EU, where it recently won its first approvals. Now, though, it's touting new data from a ...

GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s ...

OTEMTO ® 1&2 post-hoc analysis reinforces quality of life benefits provided by Spiolto ® Respimat ® right from the initial stage when patients first need maintenance therapy * Head-to-head ENERGITO ® ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiolto Respimat contains the active ingredients tiotropium (as ...

Boehringer Ingelheim's recently-approved Spiolto is more effective than GlaxoSmithKline's Seretide/Advair in improving lung function in patients with chronic obstructive pulmonary disease (COPD), ...

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A posthoc analysis from OTEMTO® 1&2 indicates that ...

In COPD, quality of life is measured using the SGRQ†; a reduction in SGRQ score of 4 points or more is deemed clinically meaningful.2 The OTEMTO® trials show Spiolto® Respimat® provides a reduction in ...

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO ® 1&2 indicates that ...

OTEMTO® trials show Spiolto® Respimat® provides clinically meaningful >4 point reduction in SGRQ score compared to placebo1These results demonstrate that Spiolto® Respimat® can bring noticeable ...

Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto ® Respimat ...